8-K: Akebia Q3 2025: Vafseo Revenue Soars, Profitability Achieved

Akebia Therapeutics reported strong third-quarter 2025 financial results, achieving net income and significant growth in Vafseo and Auryxia product revenues.

Summary

• Achieved net income of $0.5 million in the third quarter of 2025, a significant improvement from a net loss of $20.0 million in the third quarter of 2024.
• Total revenues increased to $58.8 million in Q3 2025, up from $37.4 million in Q3 2024, driven by Vafseo sales and an increase in Auryxia sales.
• Vafseo (vadadustat) net product revenues reached $14.3 million in Q3 2025, its first year of U.S. launch.
• Auryxia net product revenues were $42.5 million in Q3 2025, compared to $35.6 million in Q3 2024, despite loss of exclusivity.
• Cash and cash equivalents were approximately $166.4 million as of September 30, 2025.
• The operational pilot of Vafseo at DaVita, initiated in August at over 100 dialysis clinics, is expected to complete in November 2025, after which Vafseo is expected to be widely available to DaVita patients.
• Expected to increase total prescribing access for Vafseo across the customer base to 275,000 patients by year-end 2025, a four-fold increase from the end of Q3.
• Post-hoc data analysis from the INNO2VATE trials, presented at ASN Kidney Week 2025, demonstrated statistically significant more favorable outcomes in the composite of all-cause mortality and hospitalization for patients receiving vadadustat compared to ESAs.
• The U.S. Food and Drug Administration (FDA) did not align on Akebia's proposed path for a Phase 3 clinical trial for Vafseo in non-dialysis patients, leading to the decision not to initiate the VALOR clinical trial and not pursue a broad label for Vafseo for CKD non-dialysis dependent patients.

Sentiment

Score: 8

Explanation: The company achieved profitability, significantly increased revenues, and demonstrated strong initial uptake for its new product Vafseo, alongside positive clinical data. The setback with the FDA for a non-dialysis indication is a negative, but overall financial performance and market penetration efforts are strong.

Positives

• Achieved net income of $0.5 million in Q3 2025, a substantial turnaround from a $20.0 million net loss in Q3 2024.
• Total revenues grew by 57% year-over-year to $58.8 million in Q3 2025.
• Vafseo net product revenues reached $14.3 million in its first year of U.S. launch, demonstrating strong initial uptake.
• Auryxia net product revenues increased to $42.5 million, despite facing loss of exclusivity.
• Cash and cash equivalents of $166.4 million provide a strong financial position.
• Post-hoc data analysis from INNO2VATE trials showed statistically significant more favorable outcomes for vadadustat in all-cause mortality and hospitalization compared to ESAs.
• Expected to increase Vafseo prescribing access to 275,000 patients by year-end, a four-fold increase from Q3.
• Over 85% of US Renal Care physicians have written a Vafseo prescription since launch.
• The VOICE trial is fully enrolled, and VOCAL enrollment is progressing well.

Negatives

• The FDA did not align on Akebia's proposed path for a Phase 3 clinical trial for Vafseo in non-dialysis patients.
• Akebia will not initiate the VALOR clinical trial and will not pursue a broad label for Vafseo for CKD non-dialysis dependent patients, limiting its market expansion potential.
• Research and development expenses increased to $14.9 million in Q3 2025 from $8.5 million in Q3 2024, primarily due to increased clinical trial activities and headcount.
• Selling, general and administrative expenses increased to $29.1 million in Q3 2025 from $26.5 million in Q3 2024, largely due to higher marketing costs for the Vafseo U.S. launch and increased headcount-related costs.

Risks

• VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE), death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access.
• Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events.
• Hepatotoxicity, including hepatocellular injury and elevated serum ALT, AST, and bilirubin levels, was reported in less than 1% of patients.
• Worsening of hypertension was reported in 14% of VAFSEO patients, with serious worsening in 2.7%, and cases of hypertensive crisis have been reported.
• Seizures occurred in 1.6% of VAFSEO patients.
• Gastrointestinal (GI) erosion occurred in 6.4% of VAFSEO patients, with serious GI erosions, including GI bleeding, reported in 3.4%.
• In clinical trials for non-dialysis patients, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed with VAFSEO compared to darbepoetin alfa.
• VAFSEO has not been studied and is not recommended in patients with active malignancies.
• VAFSEO may cause fetal harm if administered to a pregnant woman.
• Breastfeeding is not recommended until two days after the final dose of VAFSEO.
• VAFSEO is not recommended in patients with cirrhosis or active, acute liver disease.
• The competitive landscape for Auryxia and Vafseo, including generic entrants and their timing, poses a risk.
• The ability to attract and retain qualified personnel is crucial for the company's operations.
• Manufacturing, supply chain, and quality matters, including potential recalls or impairments, could impact operations.
• Early termination of any of Akebia's collaborations could affect business plans.
• Changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs could impact the company.

Future Outlook

Akebia expects to close 2025 with four times the prescribing access to Vafseo compared to the end of Q3, reaching 275,000 patients, which is anticipated to accelerate broader uptake and growth in 2026. The DaVita operational pilot for Vafseo is expected to complete in November, making Vafseo widely available to DaVita patients. The company believes it is financed to achieve profitability based on its current operating plan.

Management Comments

• "Through the quarter we’ve continued to make progress against our goal to make Vafseo standard of care for the treatment of anemia for patients on dialysis and capitalize on nephrologists strong desire to prescribe Vafseo."
• "These efforts include generating incremental data, like the data Dr. Glenn Chertow presented last week at ASN Kidney Week, further informing physicians about potential additional benefits of the product, and enabling increased patient access to Vafseo."
• "To that end, we expect to close the year with four times the prescribing access to Vafseo as compared to the end of Q3, which we believe will accelerate broader uptake and growth in 2026."

Industry Context

The biopharmaceutical industry for kidney disease treatments is competitive, with a focus on innovative therapies for anemia in dialysis patients. Akebia's Vafseo (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of drugs that aims to offer an oral alternative to traditional erythropoietin-stimulating agents (ESAs). The company's efforts to expand access through major dialysis providers like DaVita and US Renal Care are critical for market penetration in this specialized sector. The post-hoc data analysis presented at ASN Kidney Week, suggesting more favorable outcomes for vadadustat compared to ESAs, could differentiate Vafseo in a market where safety and efficacy are paramount. The FDA's decision not to align on a non-dialysis indication highlights the stringent regulatory environment and the challenges of expanding drug labels beyond initial approvals.

Comparison to Industry Standards

• Vafseo's post-hoc data analysis from INNO2VATE trials, showing statistically significant more favorable outcomes in all-cause mortality and hospitalization compared to ESAs (like darbepoetin alfa), positions it favorably against established treatments. This is a critical differentiator in the anemia of CKD market, where cardiovascular safety has been a long-standing concern with ESAs.
• The rapid expansion of Vafseo access to 275,000 patients by year-end, including major players like DaVita and US Renal Care, indicates strong initial market acceptance and a competitive rollout strategy, potentially outpacing some new drug launches in specialized markets.
• Achieving net income of $0.5 million in Q3 2025, a significant turnaround from a $20.0 million net loss in Q3 2024, demonstrates effective cost management and revenue growth, which is a positive signal compared to many early-stage biopharmaceutical companies that often operate at a loss for extended periods post-launch.
• The FDA's non-alignment on a non-dialysis indication for Vafseo is a setback, as expanding into the larger non-dialysis CKD anemia market would have significantly broadened its addressable patient population, a common strategy for maximizing drug potential. This limits Vafseo's market scope compared to drugs that achieve broader labels.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, achievement of net income, strong revenue growth, and positive outlook for Vafseo uptake. The decision not to pursue a non-dialysis label for Vafseo might limit long-term market potential but reduces R&D expenditure on a potentially unapprovable indication.
• Patients (on dialysis): Potential benefit from Vafseo's expanded access and the post-hoc data suggesting more favorable outcomes in mortality and hospitalization compared to ESAs.
• Healthcare Providers (Nephrologists): Increased options for treating anemia in dialysis patients with Vafseo, supported by new clinical data.
• Employees: Positive outlook due to company growth and progress towards profitability.

Next Steps

• Complete the operational pilot of Vafseo at DaVita in November 2025.
• Increase Vafseo prescribing access to 275,000 patients by year-end 2025.
• Continue enrollment for the VOCAL clinical trial.
• Advance existing programs to achieve profitability.

Key Dates

Recommendation

The company has demonstrated a significant turnaround, achieving net income in Q3 2025 after a substantial loss in the prior year. Vafseo, a newly launched product, is showing strong initial revenue growth and expanding patient access rapidly through key partnerships like DaVita and US Renal Care. Positive post-hoc clinical data further supports its market position. While the FDA's decision on the non-dialysis indication is a setback, the focus on the approved dialysis market, coupled with a strong cash position and a stated path to sustained profitability, makes Akebia an attractive investment for growth-oriented investors.

Keywords

Akebia Therapeutics, AKBA, Vafseo, vadadustat, Auryxia, kidney disease, anemia, dialysis, biopharmaceutical, Q3 2025, financial results, SEC filing, pharmaceutical, clinical trials, FDA, INNO2VATE, ASN Kidney Week, DaVita, US Renal Care